Isomorphic Labs Raises $2.1B Series B Led by Thrive Capital

Isomorphic Labs raised $2.1B in a Series B round announced on May 12, 2026. UK-based AI-first drug design and development company.

Round size
$2.1B
Stage
Series B
Headquarters
United Kingdom
Announced
May 12, 2026

The company

UK-based AI-first drug design and development company.

The funding

Isomorphic Labs, based in London, United Kingdom, announced $2.1B in Series B financing on May 12, 2026.

Participants include Temasek, UK Sovereign AI Fund, CapitalG, Thrive Capital, Alphabet, GV.

Where the funding goes

  • Develop its AI drug design engine.
  • Advance therapeutic programs towards clinical development.

Sources

  1. Tech.eu Funding Explorer
  2. Isomorphic Labs funding announcement
03 / Related rounds

Related funding rounds

01
Series B · AI

Fractile

Fractile designs and builds AI compute systems and processors for frontier model inference.

$220M
02
Series B · Deeptech

QuantWare

QuantWare engages in designing, developing, and fabricating hardware to enable quantum computing.

€152M
03
Series B · Gaming

Grand Games

Grand Games produces new games rapidly, shortening the feedback loop from beta customers.

$70M